相关实验视频

Updated: Jun 21, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRAS^G12C抑制剂在晚期固体瘤中的有效性和毒性:一个元分析

Shoutao Dang¹, Shuyang Zhang¹, Jingyang Zhao¹

¹Cancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China.

World journal of surgical oncology

|July 15, 2024

概括

克拉斯G12C抑制剂在先进的固体瘤中显示出良好的疗效,而索托拉西布显示出更好的安全性. 这些向疗法提供了可容忍的与治疗相关的不良事件,并改善了患者的生存结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

在先进的固体瘤中研究了KRAS G12C抑制剂的疗效和毒性,但结果缺乏一致性.
克拉斯G12C突变是各种癌症的关键驱动因素,需要针对性的治疗策略.

研究的目的:

系统评估KRAS G12C抑制剂在患有晚期固体瘤的患者中的疗效和安全性.
在这个患者群体中比较索托拉西布和阿达格拉西布的安全性.

主要方法:

在PubMed,Embase和Cochrane图书馆数据库中进行了系统的文献搜索,截至2023年12月31日.
从10项涉及925名患者的临床试验中对客观反应率 (ORR),疾病控制率 (DCR),反应持续时间 (DoR),无进展生存率 (PFS),总生存率 (OS) 和与治疗相关的不良事件 (trAEs) 的综合分析.

主要成果:

聚合ORR为28.6%,DCR为85.5%,6个月的PFS为49.6%,12个月的PFS为26.7%,6个月的OS为76.2%,12个月的OS为47.8%.
任何级别的trAEs发生在79.3%的患者中,3级或更高级别的trAEs发生在24.4%的患者中.
与Adagrasib相比,索托拉西布显示任何等级和高等级的trAEs的发生率明显较低.

结论:

克拉斯G12C抑制剂表现出良好的疗效 (ORR,DCR,PFS,OS) 和可容忍的安全性,在先进的固体瘤中具有早期和持久的反应.
尽管综合结果异质,但相比阿达格拉西布,索托拉西布似乎具有更高的安全性.

关键词:

这是一种KRASG12C抑制剂.进行元分析分析.固体瘤是一种固体瘤.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...